Company news
MannKind Corporation news in 2024
MannKind Corporation's news releases, calls and decks from 2024, newest first.
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
December 17, 2024
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
December 15, 2024
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
December 10, 2024
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
November 6, 2024
MannKind to Present at 2024 UBS Healthcare Conference
November 4, 2024
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
November 3, 2024
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
October 30, 2024
More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
September 29, 2024
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
September 17, 2024
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
September 9, 2024
MannKind to Present at Upcoming Conferences
August 26, 2024
Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board
August 13, 2024
MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
August 6, 2024
MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
July 30, 2024
MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
July 29, 2024
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
June 21, 2024
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
June 4, 2024
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
May 28, 2024
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
May 7, 2024
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
May 5, 2024
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
April 30, 2024
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
April 29, 2024
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
April 28, 2024
MannKind Repays Certain Debt Obligations
April 2, 2024
MannKind Announces CFO Transition
March 25, 2024
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
March 10, 2024
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
March 4, 2024
MannKind Corporation Announces Participation at Upcoming Conferences
March 3, 2024
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
February 26, 2024
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
February 19, 2024
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
February 14, 2024
MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
January 1, 2024